Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia to be Presented at 2013 American Society of Hematology Annual Meeting 55th American Society of Hematology (ASH) Annual Meeting and Exposition Business Wire CAMBRIDGE, Mass. -- December 2, 2013 Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron’s programs to treat red blood cell disorders, will be presented at the 55^th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10^th at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a poster presentation by the first author Maria-Domenica Cappellini, M.D., University of Milan, Milan, Italy on Monday December 9^th from 6:00 – 8:00 PM CST in Hall E of the convention center. Acceleron has previously provided interim clinical data from the 0.1 mg/kg and 0.3 mg/kg dose levels in this trial. Additionally, preclinical data from both the sotatercept and ACE-536 programs will be presented at the meeting. Both sotatercept and ACE-536 are being jointly developed through a global collaboration with Celgene Corporation. The presentations from Acceleron, Celgene and academic collaborators will take place as follows: Sotatercept Clinical Data Abstract title: “A Phase 2a, Open-Label, Dose-Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults with Beta (β)-Thalassemia: Interim Results” Abstract number: 3448 Session: 112. Thalassemia and Globin Gene Regulation: Poster III Date: Monday, December 9, 2013 Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E) Sotatercept Preclinical Data Abstract title: “Sotatercept Promotes Differentiation and Survival of Erythroid Progenitors by Blocking Inhibitory Effects of TGFβ Superfamily Members” Abstract number: 944 Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster I Date: Saturday, December 7, 2013 Time: 5:30 PM – 7:30 PM CST (Ernest N. Morial Convention Center, Hall E) Abstract title: “Sotatercept, an Activin Receptor-2a Ligand Trap, Modulates Hepcidin Levels in Primary Human Hepatocytes” Abstract number: 3441 Session: 102. Regulation of Iron Metabolism: Poster III Date: Monday, December 9, 2013 Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E) Abstract title: “RAP-011 Efficiently Rescues Erythropoiesis in Zebrafish Models of Diamond Blackfan Anemia” Abstract number: 3702 Session: 508. Bone Marrow Failure: Poster III Date: Monday, December 9, 2013 Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E) ACE- 536 Preclinical Data Abstract title: “Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia in a Murine Model of Myelodysplastic Syndrome and Improves Overall Survival” Abstract number: 749 Date: Monday, December 9, 2013 Session: 633. Myelodysplastic Syndromes: Basic and Clinical Insights Time: Oral presentation at 7:15 PM CST (New Orleans Theater AB) About Sotatercept and ACE-536 Sotatercept is an activin receptor type IIA fusion protein and ACE-536 is a modified activin receptor type IIB fusion protein. Both molecules act as ligand traps for members of the TGF-β superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept and ACE-536 regulate late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Diseases like myelodysplastic syndromes (MDS) and beta-thalassemia are characterized by “ineffective erythropoiesis,” in which there is an over-production of early-stage erythrocyte precursors in the bone marrow and premature apoptosis (cell death) of later-stage precursors. Administration of EPO does not correct the underlying cause of the anemia associated with ineffective erythropoiesis. By promoting the differentiation of later-stage erythroid precursor cells into mature red blood cells, sotatercept and ACE-536 address the ineffective erythropoiesis and therefore have the potential to treat the anemia underlying both MDS and beta-thalassemia. Acceleron and Celgene are jointly developing sotatercept and ACE-536. Both molecules are currently in phase 2 clinical trials in patients with beta-thalassemia and in patients with MDS. For more information, please visit www.clinicaltrials.gov. About Acceleron Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com. Contact: Acceleron Pharma Steven Ertel, 617-649-9234 Senior Vice President and Chief Business Officer or Media: Suda Communications LLC Maureen L. Suda, 585-387-9248
Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia to be Presented at 2013 American Society
Press spacebar to pause and continue. Press esc to stop.